Hello, my name is niket and I will be your conference today. At this point, I would like to welcome all Celera First Quarter 2009 Earnings Conference Call. (Operator manual) I would like now to introduce Dr. David Speechly, Vice President of Corporate Affairs at Celera. Dr. Speechly you can begin your conference.
David Speechly, Ph.D.
Thank you very much, operator. Hello and thank you all for participation in the management Celera for the first quarter 2009 financial results, we in the early afternoon. Today, Kathy Ordoñez our Chief Executive Officer and Ugo DeBlasi our Chief Financial Officer and other leaders of Celera and Berkeley HeartLab.
During this call, the future statements about Celera business. Outlook end financial reports or advice for other reasons as conference calls or in our press releases. All the conclusions of this conference call about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts are forward-looking statements. These reports are often but not always, using words and phrases, said that, expect, anticipate, estimate, believe, intend to, plan, predict, could, should and would. For example, talk of financial advice in 2009, financial conditions, product launches, permissions and time, or the future can be expected to yield, growth, industry ranking, plans and objectives of management and future economic conditions are forward-looking statements.
Foresight is not considered as guarantees of performance. They are subject to known and unknown risks and uncertainties could cause actual results significantly expenditure expressed or implied. Factors that lead to such differences are, but are not limited to, in our SEC.
We will also discuss the history and future statements, non-GAAP Financial Measures. This non-GAAP measure is not in compliance with all other full and GAAP and non-GAAP Financial Measures, by other companies. An approximation of U.S. GAAP and non-GAAP financial.
Please note that this call after the text of these comments are prepared in the Investor Relations website Celera.
First, Kathy Ordoñez and Ugo DeBlasi is thinking, Celera's performance during the quarter and we call for questions. Kathy.
Kathy Ordoñez
Thank you, David, and all afternoon. We had a solid first quarter of 2009 as sales of more than 15% over the same quarter the previous year, with 69% gross margin for the translation result in a growth of non-GAAP basis. We are at our collections and we are pleased with the appointment of Ugo DeBlasi as our Chief Financial Officer.
Many of you know, Ugo. With his knowledge of our profession and in close collaboration with us for many years as part of the Applera has a direct impact on Celera. We believe his experience and his financial and leadership are also in the future.
The first quarter was also a very productive period for us against a large number of scientific and economic development. All that our commitment to a leading provider of genetic tests are used routinely in customization Disease Management. Achieving this goal requires that we have a wide range of genetic tests for predisposition of individual prediction of disease and treatment decisions drive. We believe we have made good progress in the development pipeline with our own findings of its own as the variance of the ONP and KIF6 genes with other data to support their marketing. In addition, this quarter we have new results of an immunoassay for the detection of lung cancer in blood samples.
David Speechly, Ph.D.
Thank you very much, operator. Hello and thank you all for participation in the management Celera for the first quarter 2009 financial results, we in the early afternoon. Today, Kathy Ordoñez our Chief Executive Officer and Ugo DeBlasi our Chief Financial Officer and other leaders of Celera and Berkeley HeartLab.
During this call, the future statements about Celera business. Outlook end financial reports or advice for other reasons as conference calls or in our press releases. All the conclusions of this conference call about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts are forward-looking statements. These reports are often but not always, using words and phrases, said that, expect, anticipate, estimate, believe, intend to, plan, predict, could, should and would. For example, talk of financial advice in 2009, financial conditions, product launches, permissions and time, or the future can be expected to yield, growth, industry ranking, plans and objectives of management and future economic conditions are forward-looking statements.
Foresight is not considered as guarantees of performance. They are subject to known and unknown risks and uncertainties could cause actual results significantly expenditure expressed or implied. Factors that lead to such differences are, but are not limited to, in our SEC.
We will also discuss the history and future statements, non-GAAP Financial Measures. This non-GAAP measure is not in compliance with all other full and GAAP and non-GAAP Financial Measures, by other companies. An approximation of U.S. GAAP and non-GAAP financial.
Please note that this call after the text of these comments are prepared in the Investor Relations website Celera.
First, Kathy Ordoñez and Ugo DeBlasi is thinking, Celera's performance during the quarter and we call for questions. Kathy.
Kathy Ordoñez
Thank you, David, and all afternoon. We had a solid first quarter of 2009 as sales of more than 15% over the same quarter the previous year, with 69% gross margin for the translation result in a growth of non-GAAP basis. We are at our collections and we are pleased with the appointment of Ugo DeBlasi as our Chief Financial Officer.
Many of you know, Ugo. With his knowledge of our profession and in close collaboration with us for many years as part of the Applera has a direct impact on Celera. We believe his experience and his financial and leadership are also in the future.
The first quarter was also a very productive period for us against a large number of scientific and economic development. All that our commitment to a leading provider of genetic tests are used routinely in customization Disease Management. Achieving this goal requires that we have a wide range of genetic tests for predisposition of individual prediction of disease and treatment decisions drive. We believe we have made good progress in the development pipeline with our own findings of its own as the variance of the ONP and KIF6 genes with other data to support their marketing. In addition, this quarter we have new results of an immunoassay for the detection of lung cancer in blood samples.
No comments:
Post a Comment